The phase 2 trial showed a 42% response rate with lete-cel in synovial sarcoma and MRCLS, with manageable adverse events.

Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Well Differentiated Liposarcoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Because liposarcoma is rare, commonly recurs, and has evolving treatments, it cannot be overemphasized that patients should be referred to specialized cancer treatment centers where a larger ...

Earlier this week, the American Cancer Society released the full list of 245 new and renewed research grants that were ...

Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...

Years ago, a family member was diagnosed with an extremely rare cancer: Liposarcoma of the Spermatic Cord. Fewer than... The ...

Officer of Adaptimmune Therapeutics PLC (NASDAQ:ADAP), executed a sale of 5,584 American Depositary Shares (ADS) on January ...

The Cork native has lost three members of her family from cancer. The Irish TV star lost her dad Sean to liposarcoma, a rare and incurable cancer when she was just 23. This Christmas ...

In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...